Vital Therapies to Host Analyst R&D Day on May 24, 2018

SAN DIEGO, May 11, 2018 (GLOBE NEWSWIRE) -- Vital Therapies, Inc. (Nasdaq:VTL), a biotherapeutic company developing ELAD®, a cell-based therapy targeting the treatment of acute forms of liver failure, will host a live webcast of its Analyst R&D Day on Thursday, May 24, 2018 beginning at 11:00 a.m. Eastern Time.  Members of the Vital Therapies team and external clinical experts in the field of alcoholic hepatitis will be presenting. The event will be held in San Diego, CA.

The live event will be accessible through the Investor Relations section of the Company’s website at  Individuals interested in participating via telephone should dial (855) 765-5682 (U.S. and Canada) or (919) 825-3204 (international) using conference ID number 4297749.

The event will be available for replay via telephone starting May 24, 2018 at approximately 4:00 p.m. Eastern Time, running through 4:00 p.m. Eastern Time on May 31, 2018. To listen to the replay, dial (855) 859-2056 (U.S. and Canada) or (404) 537-3406 (international) using conference ID number 4297749. The archived webcast will be available on Vital Therapies’ website beginning approximately four hours after the webcast has completed.

About Vital Therapies, Inc.

Vital Therapies, Inc. is a biotherapeutic company developing a cell-based therapy targeting the treatment of acute forms of liver failure.  The Company's ELAD System is an extracorporeal human allogeneic cellular liver therapy currently in phase 3 clinical trials.  Vital Therapies, Inc. is based in San Diego, California.  Vital Therapies® and ELAD® are trademarks of Vital Therapies, Inc.

Vital Therapies, Inc. 
Al Kildani
Vice President, Investor Relations and Business Development

Primary Logo

Source: Vital Therapies, Inc.